The US Food and Drug Administration announced on Friday that it has granted full approval to Pfizer and BioNTech’s COVID-19 vaccine for adolescents aged 12 to 15, Reuters reports.
The vaccine, sold under the brand name Comirnaty for adults, was available with an emergency license from May 2021 for the 12-15 age group. It will now be sold under the same brand name for teenagers as well.
The FDA said Friday that the full approval follows a rigorous analysis and evaluation of safety and efficacy data. The vaccine was approved for use in people aged 16 and over last August.
About 67% of the total US population has been fully vaccinated against COVID-19, according to federal data.
The FDA last month asked vaccine makers, including Pfizer and rival Moderna Inc MRNA.O, to change the design of their booster vaccines starting in the fall to include ingredients tailored to fight the currently prevalent subtypes Omicron BA.4 and BA.5 of the coronavirus.
I am Derek Black, an author of World Stock Market. I have a degree in creative writing and journalism from the University of Central Florida. I have a passion for writing and informing the public. I strive to be accurate and fair in my reporting, and to provide a voice for those who may not otherwise be heard.